Wolf-Henning Boehncke

Featured in: Favicon

wiley.com

thelancet.com Favicon

jacionline.org Favicon

jrheum.org Favicon

emjreviews.com Favicon

onlinelibrary.wiley.com

Articles

Deutsche Medizinische Wochenschrift / Abstract

Jan 2, 2024 | thieme-connect.de | Wolf-Henning Boehncke

Die atopische Dermatitis ist eine chronisch-rezidivierend verlaufende Entzündungsreaktion. Sie beginnt oft in der Kindheit und persistiert zum Teil bis ins hohe Erwachsenenalter. Ursächlich ist neben einer auf Mutationen von Strukturproteinen der Epidermis zurückzuführenden Störung der Hautbarriere eine gesteigerte TH2-Immunantwort.
Early detection and prevention of psoriatic arthritis

Oct 12, 2023 | bpno.dk | Wolf-Henning Boehncke

Opret en profil og få adgang til BestPractice Nordic platformen Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel, kan du:Få adgang til kliniske nyheder med relevans for dit specialeLæse artikler online og BestPractice Nordic magasinetmed nyt fra dit speciale tilsendt gratisSe MEDtalks med førende specialisterHøre MEDcasts med specialister diskutere patientcases,diagnosticerings- og behandlingsdilemmaerOg meget mere.
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis

Jun 1, 2023 | jrheum.org | Proton Rahman |Wolf-Henning Boehncke |Philip Mease |Alice Gottlieb

DISCUSSIONThese findings represent the most comprehensive safety assessment of an IL-23p19 inhibitor in PsA that we know of to date, with 1508 patients evaluated for up to 2 years (2125 PY). Integrated analyses across 4 phase II/III studies of patients with active PsA demonstrated that the safety profile of GUS remained consistent, regardless of prior TNFi or concomitant MTX use.
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis

Feb 8, 2023 | jrheum.org | Proton Rahman |Wolf-Henning Boehncke |Philip Mease |Alice Gottlieb

Thank you for your interest in spreading the word about The Journal of Rheumatology. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.